Chronic kidney disease progression with proton pump inhibitors versus H2 receptor antagonists in NSAID users
Journal of Nephrology · 30.10.2026 · 39 (8) · 1687-1696
DOI: 10.1093/joneph/aajag176 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nephrology, online erschienen am 03.09.2026. Verfasst von Susin Park und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Kyungsung University, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Histamine H2 Antagonists, Renal Insufficiency, Chronic, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Clinical evidence comparing the renal impact of proton pump inhibitors (PPIs) and Histamine-2 receptor antagonists (H2RAs) in patients with chronic kidney disease (CKD) receiving traditional non-steroidal anti-inflammatory drugs (tNSAIDs) is lacking. We evaluated CKD progression risk associated with PPIs versus H2RAs within a tNSAID-treated cohort to inform clinical prescribing.
Methods
This retrospective cohort study used South Korean nationwide claims data (2018–2023). Stabilized inverse probability of treatment weighting (SIPTW) balanced the cohorts. Restricted cubic spline Cox regression addressed non-linear associations between CKD progression and cumulative exposure to tNSAIDs and acid suppressants (PPIs or H2RAs). Sensitivity analyses addressing unspecified CKD stages confirmed the robustness of the primary findings.
Results
Among 141 093 tNSAID initiators with CKD prescribed PPIs (n = 5315) or H2RAs (n = 7112), PPIs were associated with higher CKD progression risk than H2RAs (adjusted hazard ratio [aHR] 1.38, 95% CI 1.10–1.74). Baseline comorbidities—hypertension (aHR 2.03, 95% CI 1.37–2.99]), diabetes (1.69 [1.29–2.21]), and a history of kidney disease (1.43 [1.13–1.81])—and prior diuretic use (2.00 [1.56–2.58]) were associated with increased risk of CKD progression. In contrast, dapagliflozin or empagliflozin use was protective (0.49 [0.27–0.89]). The risk of CKD progression for PPIs relative to H2RAs was most pronounced in females, those with CKD stage 3, patients aged ≥71 years, and those with 1–15 days of treatment (all P < .05).
Conclusion
Our findings suggest that H2RAs may be associated with a lower risk of CKD progression than PPIs in tNSAID users with CKD, potentially offering a safer alternative when PPI therapy is not indispensable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Kyungsung University, Busan, Republic of Korea.
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae, Gyeongnam Republic of Korea.
ORCID-Profile: Susin Park, Pusoon Chun
Zitieren
APA
Park, S., & Chun, P. (2026). Chronic kidney disease progression with proton pump inhibitors versus H2 receptor antagonists in NSAID users. Journal of Nephrology, 39(8), 1687-1696. https://doi.org/10.1093/joneph/aajag176
Vancouver
Park S, Chun P. Chronic kidney disease progression with proton pump inhibitors versus H2 receptor antagonists in NSAID users. Journal of Nephrology. 2026;39(8):1687-1696. doi:10.1093/joneph/aajag176
BibTeX
@article{Park2026,
author = {Park, Susin and Chun, Pusoon},
title = {Chronic kidney disease progression with proton pump inhibitors versus H2 receptor antagonists in NSAID users},
journal = {Journal of Nephrology},
year = {2026},
volume = {39},
number = {8},
pages = {1687--1696},
doi = {10.1093/joneph/aajag176}
}
EUVIMED